Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
← catalyst calendarNCT06922591 · readout ≤ 315 d
Sponsored by Tango Therapeutics, Inc. (industry) · TNGX — their whole pipeline →. With Revolution Medicines, Inc..
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
183estimated
Sites
18
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-05-31 | actual | When the study began enrolling |
| Primary completion | Jun 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2025-04-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- PDAC
- PDAC - Pancreatic Ductal Adenocarcinoma
- NSCLC
- RAS Mutation
- MTAP Deletion
- Lung Cancer
- Pancreatic Cancer Metastatic
- Thoracic Cancer
Interventions
- Drug: TNG462
- Drug: RMC-9805
- Drug: RMC-6236
- Drug: mFOLFIRINOX
- Drug: gemcitabine/nab-paclitaxel
Primary outcomes
what the primary-completion date above is the date OFPhase 1: Maximum Tolerated Dose
measured 21 days
Phase 1: Maximum Tolerated Dose
measured 28 days
Phase 2: Combination Anti-neoplastic Activity
measured 12 weeks
Permalink · TNGX's whole pipeline · Catalyst calendar · Every registered study · What changed